Publications by authors named "Rebecca A Previs"

Claim this Profile
T
The promise and perils of biomarker testing in gynecologic cancers.
Katherine C Fitch, Rebecca A Previs, Haley A Moss

Gynecol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.
Kyle C Strickland, Zachary D Wallen, Heidi C Ko, Michelle F Green, Alicia Dillard, Rebecca A Previs

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage.
Michelle F Green, Zachary D Wallen, Heidi C Ko, Kyle C Strickland, Alicia Dillard, Rebecca A Previs

Mol Diagn Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.
Kyle C Strickland, Zachary D Wallen, Heidi C Ko, Michelle F Green, Alicia Dillard, Rebecca A Previs

Sci Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers.
Stéphanie L Gaillard, Gloria Broadwater, Andrew Berchuck, William S Andrews, Laura J Havrilesky, Rebecca A Previs

Gynecol Oncol Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.
Angeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, Premal Thaker, Paola A Gehrig, Rebecca A Previs

Int J Gynecol Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic fusions in a real-world standard-of-care setting.
Zachary D Wallen, Marni Tierno, Erica Schnettler, Alison Roos, Michelle Green, Rebecca A Previs

Front Genet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Amma Asare, Rebecca Ann Previs, Daniel Spinosa, Bryan Fellman, Amelia L Scott

Gynecol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.
Heidi C Ko, Kyle C Strickland, Dana Jaggessarsingh, Alicia Dillard, Michelle Green, Rebecca A Previs

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.
Rebecca A Previs, Kyle C Strickland, Zachary Wallen, Heidi Ko, Michelle Green

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.
Pamela N Peters, Regina S Whitaker, Felicia Lim, Shonagh Russell, Elizabeth A Bloom, Rebecca A Previs

Neoplasia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer-a case series of divergent results from a large reference laboratory.
Kyle C Strickland, Mary K Nesline, Rebecca A Previs, Heidi Ko, Maureen Cooper

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40/OX40 ligand and its role in precision immune oncology.
Bicky Thapa, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Rebecca A Previs

Cancer Metastasis Rev· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors.
Zachary D Wallen, Mary K Nesline, Sarabjot Pabla, Shuang Gao, Erik Vanroey, Rebecca A Previs

Brief Bioinform· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.
Heidi Chwan Ko, R J Seager, Sarabjot Pabla, Maria-Fernanda Senosain, Erik Van Roey, Rebecca Ann Previs

Breast Cancer (Dove Med Press)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.
Zachary D Wallen, Heidi Ko, Mary K Nesline, Stephanie B Hastings, Kyle C Strickland, Rebecca A Previs

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Mary K Nesline, Vivek Subbiah, Rebecca A Previs, Kyle C Strickland, Heidi Ko

Oncol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting Enhanced Recovery After Surgery (ERAS) Protocols to Promote Equity in Cancer Care and Outcomes.
Clare Meernik, Michaela Z Kolarova, Melina Ksor, Samantha Kaplan, Julie K Marosky Thacker, Rebecca A Previs

Ann Surg Open· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
Robert J Seager, Heidi Ko, Sarabjot Pabla, Maria-Fernanda Senosain, Pawel Kalinski, Rebecca Ann Previs

J Pers Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Heidi Ko, Rebecca A Previs, Kyle C Strickland, Jonathan Klein, Brian Caveney

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer.
Shama Karanth, Oyomoare L Osazuwa-Peters, Lauren E Wilson, Rebecca A Previs, Fariha Rahman

Cancer Res Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.
R J Seager, Maria-Fernanda Senosain, Erik Van Roey, Shuang Gao, Paul DePietro, Rebecca A Previs

J Transl Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes.
Jacob J Adashek, Shumei Kato, Daisuke Nishizaki, Sarabjot Pabla, Mary K Nesline, Rebecca A Previs

Am J Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series.
Benjamin B Albright, Stephanie Shuey, Angeles Alvarez Secord, Laura J Havrilesky, Andrew Berchuck, Rebecca A Previs

Gynecol Oncol Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
Abhinava K Mishra, Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty, Rebecca Ann Previs

Vaccines (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis